169 related articles for article (PubMed ID: 7020365)
21. Adenosine A(2A) receptor-mediated modulation of GABA and glutamate release in the output regions of the basal ganglia in a rodent model of Parkinson's disease.
Ochi M; Shiozaki S; Kase H
Neuroscience; 2004; 127(1):223-31. PubMed ID: 15219684
[TBL] [Abstract][Full Text] [Related]
22. Zonisamide enhances delta receptor-associated neurotransmitter release in striato-pallidal pathway.
Yamamura S; Ohoyama K; Nagase H; Okada M
Neuropharmacology; 2009 Sep; 57(3):322-31. PubMed ID: 19482038
[TBL] [Abstract][Full Text] [Related]
23. GABAergic mechanisms in regulating the activity state of substantia nigra pars reticulata neurons.
Windels F; Kiyatkin EA
Neuroscience; 2006 Jul; 140(4):1289-99. PubMed ID: 16713116
[TBL] [Abstract][Full Text] [Related]
24. [Anatomical connections of the basal ganglia].
Fujiyama F
Brain Nerve; 2009 Apr; 61(4):341-9. PubMed ID: 19378803
[TBL] [Abstract][Full Text] [Related]
25. Interactions between dopamine D1 receptors and gamma-aminobutyric acid mechanisms in substantia nigra pars reticulata of the rat: neurochemical and behavioral studies.
Trevitt T; Carlson B; Correa M; Keene A; Morales M; Salamone JD
Psychopharmacology (Berl); 2002 Jan; 159(3):229-37. PubMed ID: 11862355
[TBL] [Abstract][Full Text] [Related]
26. Fos expression following activation of the ventral pallidum in normal rats and in a model of Parkinson's Disease: implications for limbic system and basal ganglia interactions.
Turner MS; Gray TS; Mickiewicz AL; Napier TC
Brain Struct Funct; 2008 Sep; 213(1-2):197-213. PubMed ID: 18663473
[TBL] [Abstract][Full Text] [Related]
27. Effects of manipulating pallidal and nigral GABA on striatally-mediated head-turning in the rat [proceedings].
Crossman AR; Lee LA; Slater P
Br J Pharmacol; 1977 Nov; 61(3):483P. PubMed ID: 563262
[No Abstract] [Full Text] [Related]
28. The GABA uptake inhibitor beta-alanine reduces pilocarpine-induced tremor and increases extracellular GABA in substantia nigra pars reticulata as measured by microdialysis.
Ishiwari K; Mingote S; Correa M; Trevitt JT; Carlson BB; Salamone JD
J Neurosci Methods; 2004 Dec; 140(1-2):39-46. PubMed ID: 15589332
[TBL] [Abstract][Full Text] [Related]
29. Modulation of methylenedioxymethamphetamine-induced striatal dopamine release by the interaction between serotonin and gamma-aminobutyric acid in the substantia nigra.
Yamamoto BK; Nash JF; Gudelsky GA
J Pharmacol Exp Ther; 1995 Jun; 273(3):1063-70. PubMed ID: 7791076
[TBL] [Abstract][Full Text] [Related]
30. Change of extracellular glutamate and gamma-aminobutyric acid in substantia nigra and globus pallidus during electrical stimulation of subthalamic nucleus in epileptic rats.
Zhang B; Chu J; Zhang J; Ma Y
Stereotact Funct Neurosurg; 2008; 86(4):208-15. PubMed ID: 18480598
[TBL] [Abstract][Full Text] [Related]
31. Subthalamic nucleus lesions alter basal and dopamine agonist stimulated electrophysiological output from the rat basal ganglia.
Zahr NM; Martin LP; Waszczak BL
Synapse; 2004 Nov; 54(2):119-28. PubMed ID: 15352137
[TBL] [Abstract][Full Text] [Related]
32. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation.
During MJ; Kaplitt MG; Stern MB; Eidelberg D
Hum Gene Ther; 2001 Aug; 12(12):1589-91. PubMed ID: 11529246
[TBL] [Abstract][Full Text] [Related]
33. Dopamine D2, receptor-mediated modulation of the GABAergic inhibition of substantia nigra pars reticulata neurons.
Martin LP; Waszczak BL
Brain Res; 1996 Aug; 729(2):156-69. PubMed ID: 8876984
[TBL] [Abstract][Full Text] [Related]
34. Substantia nigra glutamate antagonists produce contralateral turning and basal ganglia Fos expression: interactions with D1 and D2 dopamine receptor agonists.
McPherson RJ; Marshall JF
Synapse; 2000 Jun; 36(3):194-204. PubMed ID: 10819899
[TBL] [Abstract][Full Text] [Related]
35. Influence of the frequency parameter on extracellular glutamate and gamma-aminobutyric acid in substantia nigra and globus pallidus during electrical stimulation of subthalamic nucleus in rats.
Windels F; Bruet N; Poupard A; Feuerstein C; Bertrand A; Savasta M
J Neurosci Res; 2003 Apr; 72(2):259-67. PubMed ID: 12672001
[TBL] [Abstract][Full Text] [Related]
36. GABAergic neurotransmission in globus pallidus and its involvement in neurologic disorders.
Chen L; Yung WH
Sheng Li Xue Bao; 2004 Aug; 56(4):427-35. PubMed ID: 15322674
[TBL] [Abstract][Full Text] [Related]
37. Dopaminergic--GABA-ergic interaction in the nigrostriatal system.
Koltai MZ; György L
Acta Physiol Acad Sci Hung; 1981; 58(3):225-33. PubMed ID: 7348023
[TBL] [Abstract][Full Text] [Related]
38. Cataleptic and anticataleptic effects of muscimol and gabaculine injected into globus pallidus and substantia nigra, and interactions with haloperidol or benzodiazepines.
Matsui Y; Kamioka T
Naunyn Schmiedebergs Arch Pharmacol; 1978 Dec; 305(3):219-25. PubMed ID: 33340
[TBL] [Abstract][Full Text] [Related]
39. Responses of substantia nigra pars reticulata and globus pallidus complex to high frequency stimulation of the subthalamic nucleus in rats: electrophysiological data.
Benazzouz A; Piallat B; Pollak P; Benabid AL
Neurosci Lett; 1995 Apr; 189(2):77-80. PubMed ID: 7609923
[TBL] [Abstract][Full Text] [Related]
40. Cerebral glucose utilization following striatal lesions: the effects of the GABA agonist, muscimol, and the dopaminergic agonist, apomorphine.
Kelly PA; McCulloch J
Brain Res; 1987 Nov; 425(2):290-300. PubMed ID: 3427431
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
